SuperGen inks oncology agreement with Molecular Response
SAN DIEGO—Privately held Molecular Response, a molecular diagnostic service company leading the field in identification of target populations for high-value therapeutics, recently announced the formation of an oncology agreement with Dublin, Calif.-based SuperGen Inc., a pharmaceutical firm targeting the development of cancer therapeutics in epigenetic and cell-signaling modulation. Under the agreement, SuperGen will gain limited access to Molecular Response's proprietary "living" cell bank of primary tumor cells, high-content imaging and molecular characterization platforms. No financial details for the agreement were released.
Cyrus K. Mirsaidi, Molecular Response's CEO, said in a press release that "we believe our high- resolution, high-content cell-based platforms and exclusive patient-derived primary tumor cell bank provide the best model for predicting efficacy of novel drugs. I expect our collaboration with SuperGen to set a leading example in translational medicine."